ECP 2019 Final Programme

Monday, 9 Sept 40 ECP 2019 · Nice Scientific Programme a Monday OFP-04 Oral Free Paper Session 08:30–12:00 Galliéni 4 Breast Pathology Chairs: Philippe Bertheau, France Janina Kulka, Hungary Thomas Decker, Germany 001 08:30–08:40 Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands Carmen van Dooijeweert, The Netherlands I. Deckers, I. Baas, E. van der Wall, P. van Diest 002 08:40–08:50 Significant inter- and intra-laboratory variation in grading of invasive breast cancer: a nationwide study of 33,043 patients in the Netherlands Carmen van Dooijeweert, The Netherlands P. van Diest, S. Willems, C. Kuijpers, E. van der Wall, L. Overbeek, I. Deckers 003 08:50–09:00 The prognostic value of the tumour-stroma ratio validates in subgroups of breast cancer, especially in grade III tumours Wilma Mesker, The Netherlands K. Vangangelt, A. Green, I. Heemskerk, D. Cohen, H. Putter, E. Rakha, R. Tollenaar 004 09:00–09:10 High Pregnane-X-Receptor (PXR) expression is correlated with poor prognosis in invasive breast carcinoma Despoina Pouloudi, Greece C. Giaginis, S. Gourzi, P. Alexandrou, G. Tsourouflis, A. Michail, N. Tsoukalas, S. Albesher, P. Politis, L. Nakopoulou, S. Theocharis 005 09:10–09:20 The immune microenvironment in young patients with Triple Negative Breast Cancer Hayley McKenzie, United Kingdom G. Martland, D. Eccles, E. Copson, G. Thomas 007 10:30–10:40 Correlation of the results of Ki67 in intristic subtypes of invasive breast carcinomas with the effect of systemic neoadjuvant treatment Wojciech P. Olszewski, Poland M. Chraszczewska, J. Plisiecka 008 10:40–10:50 Independent HER2-targeted therapy resistance predictors: intratumoural heterogeneity in breast carcinoma HER2 gene copy number and protein expression Hiro Nitta, USA R. Horii, R. Maruyama, M. Nojima, M. Matsuura, D. Munroe, P. Banks, F. Akiyama 009 10:50–11:00 Investigation of microRNA expression profiles related to morphological heteroge- neity in triple-negative breast cancer Marketa Koleckova, Czech Republic Z. Kolar, J. Ehrmann, M. Svoboda, O. Slaby, J. Bouchal, K. Bouchalova, M. Janikova, J. Srovnal, L. Radova 010 11:00–11:10 Ultra-fast and automated immunohistofluo- rescent multistaining using a microfluidic tissue processor Marta Aurelia Comino, Switzerland G. Cappi, D. G. Dupouy, A. T. Ciftlik 011 11:10–11:20 PD-L1 testing in triple negative breast cancer Florin-Costel Dobritoiu, Romania A. Chefani, K. Billingham, M. Chenard, R. Vaziri, M. Lacroix Triki, A. Waydelich, G. Erb, P. Toro, S. Wedden, C. D ‘ Arrigo